Noteworthy SangStat readies move into generic

SangStat Medical Corp. was to announce today that it has formed two alliances for the development of a generic cyclosporine product for the organ transplantation market.

SANG has acquired exclusive worldwide technology rights from an undisclosed private biopharmaceutical company for development of a formulation of cyclosporine. The Menlo Park, Calif., company also has contracted for the large-scale production of cyclosporine